Tiny nucleic acid molecule biomarker combination with plateau adaptability and kit thereof
By detecting the expression levels of hsa-miR-4290 and hsa-miR-877-3p in plasma during plateau, a biomarker combination is provided, which solves the problem of difficult to predict individual plateau adaptability in the prior art, and realizes the plateau Accurate assessment and screening of adaptability mitigates the impact of altitude sickness on populations and health institutions.
Patent Information
- Application Number
- CN202411163104.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively predict individual plateau adaptability, leading to the occurrence of plateau diseases, which has serious impacts on health institutions in plateau areas and people who are rapidly advancing plateaus.
By detecting the expression levels of hsa-miR-4290 and hsa-miR-877-3p in plasma during the plain of the subject, a micronucleic acid molecule biomarker combination is provided to screen individual plateau adaptability and develop corresponding Kits for detecting the expression levels of these microRNAs.
This method can significantly distinguish between those who are well-adapted on the plateau and those who are maladapted on the plateau, provide a minimally invasive, safe and convenient prediction and evaluation method, reduce the threat of maladaptive on the health and life of people, and improve the safety of emergency rescue in the plateau area.
Smart Images

Figure CN118932077A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular biotechnology and its application, and relates to a plateau-adaptive micro-nucleic acid molecule biomarker combination and a kit thereof. Background Art
[0002] When people from the plains suddenly enter the plateau area at an altitude of 2,500 meters, low pressure and low oxygen can cause a significant drop in the body's blood oxygen content, which makes it impossible to meet the oxygen needs of tissue cells and damage the normal physiological function homeostasis. For this kind of physiological function homeostasis damage, some people can establish a good plateau adaptation mechanism through their own adjustments to maintain physiological function homeostasis, and work and live well in the plateau environment. They are medically called high altitude adaption (HAA). Another group of people are high-altitude maladaption (HAM), who have poor adaptability to plateau hypoxia and cannot quickly establish a plateau adaptation mechanism, which leads to the occurrence of acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE) and high-altitude cerebraledema (HACE). In mild cases, it seriously affects the daily quality of life of people who rush to the plateau, reduces their work ability or causes disability. In severe cases, it can lead to death, seriously threatening their life and health (Pham, K., K. Parikh and EC Heinrich, Hypoxia and Inflammation: Insights From High-Altitude Physiology. "Frontiers in physiology", 2021.12: p.676782).
[0003] The strength of plateau adaptability has an obvious genetic tendency. The environmental altitude, the speed of entering the plateau and genetic factors can all affect the individual's plateau adaptability. Therefore, it will be of great significance to screen out biological indicators that can show excellent plateau adaptability levels. For example, in the prior art, the application number is 202110773375.1, and the patent name is a SNP marker and a kit for detecting plateau adaptability. A SNP marker for detecting plateau adaptability is provided, and the SNP marker is rs1204168. The genotype of rs1204168 CC or TC is an indication that the human body has plateau adaptability.
[0004] In recent years, with the vigorous development of plateau tourism and plateau economy at home and abroad, more than 20 million people now travel back and forth from the plains to the plateau every year (Gao Yuqi. Plateau Military Medicine [M]. Chongqing Publishing House, 2005; Liu Hao, Hou Yunpeng, Ran Zhuang, et al. Monitoring of common air indicators in the Qinghai-Tibet Plateau oxygen supply train compartment and its impact on human comfort. Journal of Preventive Medicine of the People's Liberation Army, 2020.). The high incidence of acute mountain sickness caused by high-altitude maladaption (HAM) not only has a very serious impact on their lives and work, but also imposes a heavy burden on health institutions in plateau areas. Therefore, it is urgent to find an effective method for predicting and diagnosing individual plateau adaptability in the plains, especially an accurate detection method using biomarkers as a detection method. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide a combination of micronucleic acid molecule biomarkers for plateau adaptability, by detecting the expression levels of hsa-miR-4290 and hsa-miR-877-3p in the plasma of the subject when in the plain, to assess in advance the adaptability of the individual after entering the plateau. Also provided are the application and kit of such microRNA molecular markers. Blood circulating microRNA has the potential to be used as a biomarker for predicting individual plateau adaptability, and is suitable for early assessment of plateau adaptability of people in the plains and screening those who are well adapted to the plateau.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] The first object of the present invention is to provide a combination of hsa-miR-877-3p and hsa-miR-4290 as a biomarker composition for screening the plateau adaptability of individuals after acute exposure to plateau.
[0008] Further, in some specific embodiments, the sequence of hsa-miR-877-3p is shown as SEQ ID No.5, and the sequence of hsa-miR-4290 is shown as SEQ ID No.1.
[0009] Furthermore, in this application, specifically, the expression level of hsa-miR-4290 or / and hsa-miR-877-3p in the plasma of the subject is detected, and the expression of the nucleic acid molecule in the plasma of those who are well adapted to the plateau (HAA) is upregulated compared with the expression in the plasma of those who are maladapted to the plateau (HAM).
[0010] Furthermore, the plasma is plasma obtained by centrifugation of peripheral venous blood taken in the morning on an empty stomach.
[0011] Furthermore, the plasma is obtained by collecting fasting peripheral venous blood in the morning using an EDTA-Na anticoagulation blood collection tube, centrifuging at 3000 rpm and 25°C for 10 minutes, and then taking the supernatant (plasma) with an RNase-free and bacteria-free pipette tip and placing it in a sterile enzyme-free EP tube and storing it at -80°C for later use.
[0012] The second object of the present invention is to provide a reagent for detecting hsa-miR-877-3p and hsa-miR-4290 for use in preparing a reagent or a kit for screening plateau adaptability.
[0013] Furthermore, the reagents are primers, probes and / or chips for detecting hsa-miR-877-3p and hsa-miR-4290 respectively.
[0014] Further, in some specific embodiments, the primer is a stem-loop RT primer.
[0015] Third, the present invention also provides a kit for screening plateau adaptability, which can detect two microRNAs, hsa-miR-4290 and hsa-miR-877-3p, and the kit contains reverse transcription primers that can specifically bind to hsa-miR-4290 or hsa-miR-877-3p for reverse transcription.
[0016] Further, in some specific embodiments, the reverse transcription primer that specifically binds to hsa-miR-4290 for reverse transcription is shown in SEQ ID No.2.
[0017] Furthermore, the reverse transcription primer that specifically binds to hsa-miR-877-3p for reverse transcription is shown in SEQ ID No.6.
[0018] Furthermore, the kit also includes primers that can specifically bind to the reverse transcription products of hsa-miR-4290 or hsa-miR-877-3p and perform qPCR amplification.
[0019] Further, in some specific embodiments, the hsa-miR-4290 forward primer sequence is shown as SEQ ID No.3, and the hsa-miR-4290 reverse primer sequence is shown as SEQ ID No.4.
[0020] Furthermore, the hsa-miR-877-3p forward primer sequence is shown in SEQ ID No.7, and the hsa-miR-877-3p reverse primer sequence is shown in SEQ ID No.8.
[0021] Furthermore, the kit for screening plateau adaptability also includes 5x reverse transcription Buffer, RTase Mix and RNase-free H2O.
[0022] Further, in some specific embodiments, the kit for screening plateau adaptability also includes a microRNA reverse transcription (RT) reaction system, and the microRNA RT reaction system includes, per 10uL, 1uL of stem-loop RT primer, 2uL of 5xreverse transcription Buffer, 2uL of RTase Mix, 3uL of RNase-free H2O, and the remaining 2uL is sample RNA.
[0023] Furthermore, the sample RNA was derived from plasma.
[0024] Furthermore, the sample RNA was derived from plasma after centrifugation of peripheral venous blood collected in the early morning on an empty stomach.
[0025] Furthermore, the RT reaction temperature parameters of the kit are: 42°C for 60 min, 70°C for 10 min.
[0026] Furthermore, the kit also includes a microRNA qPCR reaction system, and the microRNA qPCR reaction system includes: 10uL SYBR Green Mix, 0.8uL microRNA qPCR Forward primer, 0.8uL microRNA qPCR Reverse primer, 6uL ddH2O, and the rest is 2uL RT reaction product per 20uL.
[0027] Furthermore, the microRNA qPCR reaction conditions of the kit are pre-denaturation at 95°C for 10 min, denaturation at 95°C for 2 s, annealing at 60°C for 20 s, and extension at 70°C for 10 s.
[0028] The beneficial effect of the present invention is that: the present invention screens the plasma circulating microRNA chip spectrum of the plain dwellers in the plains, and after they are rapidly entering the plateau, according to the "National Military Standard for Plateau Acclimatization (Adaptation): GJB4301-2002" (Gao Yuqi. Plateau Military Medicine [M]. Chongqing Publishing House, 2005.), the system distinguishes the people with good plateau adaptation and the people with poor plateau adaptation, and further finds that there are significant differences in the circulating hsa-miR-4290 and hsa-miR-877-3p in the plasma of the plains between the HAA and HAM populations in combination with their good or poor plateau adaptation after plateau hypoxia exposure. Then, the expression levels of hsa-miR-4290 and hsa-miR-877-3p in the plasma circulation of another independent population in the plains are detected by the chimeric fluorescent dye real-time fluorescence quantitative PCR method, which confirms that there is a relatively close correlation between the expression levels of hsa-miR-4290 and hsa-miR-877-3p in the plasma circulation in the plains and the plateau adaptability differences, and has a good predictive evaluation efficiency for plateau adaptability. These two tiny nucleic acid molecules can be used independently or in combination as biomarkers to screen for good or poor adaptation to the plateau. On the one hand, this is conducive to the safe and effective implementation of emergency rescue activities in plateau areas; on the other hand, it can guide the early targeted protection of those who are poorly adapted to the plateau, and reduce the threat of poor adaptation to human health and life.
[0029] The microRNA markers proposed in the present invention can be detected through plasma, and sample acquisition has the advantages of being minimally invasive, safe, convenient and highly acceptable. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:
[0031] Figure 1 The volcano plot of the difference in microRNA expression in plasma between the high altitude adaptation (HAA) group and the high altitude adaptation (HAM) group in the plain;
[0032] Figure 2 The melting curves of each target microRNA qPCR reaction, including: A: hsa-miR-4290; B: hsa-miR-877-3p;
[0033] Figure 3 Comparison of relative expression levels of hsa-miR-4290 in plasma between subjects with good plateau adaptation and subjects with poor plateau adaptation;
[0034] Figure 4 The working characteristic curve of hsa-miR-4290 in plasma of people who are well adapted to the plateau;
[0035] Figure 5Comparison of relative expression levels of hsa-miR-877-3p in plasma between subjects with good plateau adaptation and subjects with poor plateau adaptation;
[0036] Figure 6 The working characteristic curve of hsa-miR-877-3p in plasma of people who are well adapted to the plateau;
[0037] Figure 7 This is the operating characteristic curve of the combination of hsa-miR-4290 and hsa-miR-877-3p in the plasma of people who are well adapted to the plateau. DETAILED DESCRIPTION
[0038] The preferred embodiment of the present invention will be described clearly and completely below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. The experimental methods for which specific conditions are not specified in the embodiments are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0039] Example 1 Screening of differential microRNA expression profiles in plasma of people with good high altitude adaptation (HAA) and poor high-altitude maladaption (HAM)
[0040] Firstly, the plasma microRNA expression profiles of different plateau adaptability in the plain were compared and analyzed. The samples for expression profile screening were from 8 subjects with good plateau adaption (HAA) and 9 subjects with poor plateau adaption (HAM). The correlation between each microRNA and the strength of plateau adaptability was studied, and potential microRNA biomarkers related to plateau adaptability were screened out. The clinical data information of the microRNA expression profile screening population is shown in Table 1.
[0041] Table 1 Clinical data of microRNA screening population
[0042]
[0043]
[0044] Note: HAA: good plateau adaptation; HAM: poor plateau adaptation; Normal distribution data are expressed as mean ± standard deviation, and non-normal distribution data are expressed as median (interquartile range).
[0045] 1. Materials
[0046] First, peripheral blood samples were collected from the above-mentioned people who were going to quickly enter the plateau from the plain. After the people entered the plateau, the HAA and HAM people were systematically distinguished based on the "National Military Standard for Plateau Acclimatization (Adaptation): GJB4301-2002" (Gao Yuqi. Plateau Military Medicine [M]. Chongqing Publishing House, 2005.).
[0047] 2. Methods:
[0048] Steps for specimen collection and plateau acclimatization assessment:
[0049] (1) The plasma collection procedure is to use EDTA-Na anticoagulant tubes to collect 5 mL of peripheral blood from the above-mentioned personnel in the morning when they are in the plains (before entering the plateau), centrifuge at 3000 rpm, 25°C for 10 minutes, and then use RNase-free and bacteria-free pipette tips to collect plasma and place it in a sterile enzyme-free EP tube and store it at -80°C for later use.
[0050] (2) Evaluation criteria for the acclimatization of people from the plains to the plateau (National Military Standard for Plateau Acclimatization: GJB4301-2002):
[0051] If a person from the plain enters the plateau within 7 days and meets the following conditions, he / she will be judged as having good adaptation to the plateau; if he / she does not meet the conditions, he / she will be judged as having poor adaptation to the plateau;
[0052] ① No severe acute mountain sickness (high altitude cerebral edema (HACE) and high altitude pulmonary edema (HAPE)) occurs, and the symptoms of acute mild mountain sickness (AMS) basically disappear (symptom score is less than 4 points);
[0053] ② In the resting state, physiological indicators tend to be stable;
[0054] ③No obvious discomfort after light physical labor.
[0055] Experimental steps in the screening phase:
[0056] (1) Plasma Total RNA Extraction and Purification
[0057] 500 μL plasma total RNA was extracted using TRIzol LS Reagent (Invitrogen, USA, Catalog No.: 10296010), and then RNA was purified and concentration was measured using RNeasy mini kit (QIAGEN, Germany, Catalog No.: 74106).
[0058] (2) Preparation of microRNA fluorescently labeled probes and biochip hybridization reaction
[0059] The preparation of fluorescently labeled probes for microRNA was achieved by using miRCURYTM Array Power Labeling kit (Exiqon, Denmark, catalog number: 208032-a). The specific operation steps were carried out according to the instructions. The biochip hybridization experiment used miRCURYTM LNA Array (Exiqon, Denmark, model: v.18.0) and was operated according to the instructions.
[0060] (3) Chip image acquisition and analysis
[0061] A microarray gene chip scanner (Axon, USA, model: GENEPIX 4000B) was used to scan the biochip signal and collect images. Afterwards, the biochip scanning analysis software GenePix Pro (Axon, USA, model: v.6.0) was used to extract the chip scanning data and perform median normalization on the chip signal. The above operations were performed according to the instrument and software instructions.
[0062] (4) Statistical analysis of plasma microRNA expression profiles
[0063] The R language software package was used to perform statistical analysis on the acquired data, and microRNAs with significant differences between the high altitude adaptation (HAA) and high altitude maladaptation (HAM) groups were screened out (screening criteria: Fold Change ≥ 2, P-value < 0.05). A total of more than 2,000 microRNAs were detected in the screening experiment. After statistical analysis, it was found that some microRNAs in plasma, including hsa-miR-4290 and hsa-miR-877-3p, were significantly differently expressed between the high altitude adaptation (HAA) and high altitude maladaptation (HAM) groups. Figure 1 The volcano diagram shows the results of differential microRNA screening between the well-adapted (HAA) and poorly adapted (HAM) people. Among them: red dots: microRNAs that are significantly upregulated in the well-adapted (HAA) group compared with the poorly adapted (HAM) group; blue dots: microRNAs that are significantly downregulated in the well-adapted (HAA) group compared with the poorly adapted (HAM) group; gray dots: microRNAs that are not differentially expressed between the two groups; FC: Fold Change, i.e., fold difference; pVal, i.e., statistical p value.
[0064] In order to verify the accuracy of plasma sample microRNA as a diagnostic biomarker, the verification team used real-time fluorescence quantitative qRT-PCR to detect the expression levels of multiple microRNAs. The results showed that the expression trend of the screened microRNAs was consistent with the chip detection results. Only experimental data related to the present invention are shown below.
[0065] Example 2 Study on the predictive efficacy of microRNA expression levels in plasma samples for plateau adaptability
[0066] The expression distribution of some microRNAs including hsa-miR-4290 and hsa-miR-877-3p in high altitude adaption (HAA) (n=29) and high altitude maladaptation (HAM) (n=30) was detected in another independent population using qPCR technology, and it was found that these two microRNAs were well correlated with HAA. During the whole process, plasma RNA was extracted using the microRNA column extraction kit (miRNeasy Serum / Plasma Kit, Catalog No.: 217184) of Qiagen Technology Co., Ltd., Germany, and then real-time fluorescence quantitative PCR (Bulge-Loop TM miRNA qRT-PCR Starter Kit, catalog number: C10211-1) was used to amplify each microRNA and the external reference cel-miR-39; the specific operation steps were carried out according to the operation manual of each kit. Then the normalized expression level of each microRNA in each specimen to the external reference cel-miR-39 was calculated, and the results were tested by SPSS19.0 and MedCalc 19.20. The ROC curve was statistically analyzed, and P < 0.05 was used as the significance test standard. It was found that there were significant differences in the expression levels of microRNAs including hsa-miR-4290 and hsa-miR-877-3p in the plasma of the HAA group and the HAM group, which can be used as biomarkers for detecting or diagnosing plateau adaptability.
[0067] 1. Materials and specimen collection description
[0068] First, peripheral blood samples were collected from the above-mentioned people who were about to enter the plateau quickly from the plain. The diagnosis of good or poor plateau adaptation was confirmed and distinguished according to the "National Military Standard for Plateau Acclimatization (Adaptation): GJB4301-2002" (Gao Yuqi. Plateau Military Medicine [M]. Chongqing Publishing House, 2005.). Plasma samples of the HAA group were collected from the plasma of people who had good plateau adaptation after acutely entering the plateau from the plain, totaling 29 cases. Plasma samples of the HAM group were collected from the plasma of people who had poor plateau adaptation after acutely entering the plateau from the plain, totaling 30 cases (clinical data are shown in Table 2). 5 mL of fasting peripheral blood was collected from the above-mentioned people in the morning when they were on the plain (before entering the plateau) using EDTA-Na anticoagulant tubes, centrifuged at 3000 rpm and 25°C for 10 minutes, and then the plasma was collected using RNAse-free and bacteria-free pipette tips and placed in sterile enzyme-free EP tubes at -80°C for storage. This study has been reviewed and approved by the Medical Ethics Committee, and all specimens were collected with informed consent from the patients.
[0069] Table 2 Clinical data of subjects with plasma specimens
[0070]
[0071] Note: HAA: good plateau adaptation; HAM: poor plateau adaptation; Normal distribution data are expressed as mean ± standard deviation, and non-normal distribution data are expressed as median (interquartile range).
[0072] 2. Specimen Collection, RNA Extraction and cDNA Synthesis
[0073] In the early morning (8:00am), 5 mL of fasting peripheral venous whole blood was collected from the subjects using EDTA-Na anticoagulation tubes. After centrifugation at 3000 rpm and 25°C for 10 minutes, plasma was collected using an RNase-free and bacteria-free pipette tip and placed in a sterile enzyme-free EP tube at -80°C for future use. RNA in all plasma samples was extracted and purified using the microRNA column extraction kit (miRNeasy Serum / Plasma Kit, catalog number: 217184) of Qiagen Technology Co., Ltd., Germany, according to the instructions.
[0074] 1. Plasma RNA concentration: 20-50ng / uL.
[0075] 2. cDNA synthesis was performed using a microRNA fluorescent quantitative PCR reverse transcription kit (Bulge-Loop TM miRNA qRT-PCR Starter Kit).
[0076] 3. microRNA cDNA synthesis system: The basic information of hsa-miR-4290 and hsa-miR-877-3p is shown in Table 3; the preparation of the reverse transcription reaction system is as shown in Table 4, and the stem-loop reverse transcription primer sequences of hsa-miR-4290 and hsa-miR-877-3p are shown in Table 5.
[0077] 4. Reverse transcription (RT) reaction temperature parameters: 42°C for 60 min, 70°C for 10 min.
[0078] Table 3 Basic information of microRNA
[0079]
[0080] Table 4 Preparation of microRNA reverse transcription system
[0081]
[0082] Table 5 Stem-loop reverse transcription primer sequences
[0083]
[0084] 3. Real-time fluorescence quantitative PCR (qPCR, chimeric fluorescent dye method)
[0085] Real-time fluorescence quantitative PCR was used to amplify hsa-miR-4290 and hsa-miR-877-3p (target microRNA) and external reference cel-miR-39; Ct values (cycle threshold) were obtained respectively, and the expression level was expressed as 2 Ct(cel-miR-39)-Ct(目标microRNA) The expression level of microRNA in each specimen was calculated. The experiment was repeated three times for each sample.
[0086] 1. Amplification reaction system: Prepare the qPCR reaction system according to Table 6; the microRNA qPCR primer sequences are shown in Table 7.
[0087] 2. Reaction conditions: pre-denaturation at 95°C for 10 min, denaturation at 95°C for 2 s, annealing at 60°C for 20 s, extension at 70°C for 10 s;
[0088] 3. The Realtime PCR amplification curves of the microRNA to be detected and the external reference cel-miR-39 both showed an "S" shape;
[0089] 4. The melting curves of PCR products are all single peaks, indicating that the amplified target gene has good specificity and the results are reliable. Figure 2 Melting curves of qPCR reactions of target microRNAs, including: A: hsa-miR-4290; B: hsa-miR-877-3p.
[0090] Table 6 Preparation of microRNA qPCR reaction system
[0091]
[0092] Table 7 microRNA qPCR primer sequences
[0093]
[0094] Statistical analysis methods
[0095] SPSS19.0 and MedCalc 19.20 were used for statistical analysis. The Shapiro-Wilk method was used for normality test, the independent sample t-test was used for significant differences in normal distribution data, and the Mann-Whitney Test was used for significant differences in non-normal distribution data. The receiver operating characteristic curve (ROC curve) and the area under the curve (AUC) were used to evaluate the screening efficiency of each microRNA (hsa-miR-4290 and hsa-miR-877-3p). When P < 0.05, it was considered to be statistically significant. Among them, AUC reflects the predictive efficiency (AUC = 0.5, no predictive efficiency; 0.5 < AUC < 0.7, very small predictive value; 0.7 < AUC < 0.9, quite accurate predictive value; 0.9 < AUC < 1, very accurate predictive value).
[0096] V. Results Analysis
[0097] 1. Figure 3 Comparison of hsa-miR-4290 expression levels in plasma between the high altitude adaptation (HAA) group and the high altitude adaptation (HAM) group; Figure 3 As shown in the figure, the expression of hsa-miR-4290 in plasma between the high altitude adaptation (HAA) group and the high altitude adaptation (poor) group was significantly different when P<0.01. When P<0.05, there was a significant statistical difference, and when P<0.01, there was a very significant statistical difference.
[0098] 2. Figure 4 Figure 2 is the operating characteristic curve of hsa-miR-4290 in plasma of people with good altitude adaptation (HAA). Figure 4As shown in the figure, the screening efficacy of plasma hsa-miR-4290 between those who are well adapted to the plateau (HAA) and those who are poorly adapted to the plateau (HAM) can be known through the ROC curve. The screening efficacy of hsa-miR-4290 in plasma between those who are well adapted to the plateau (HAA) and those who are poorly adapted to the plateau (HAM) is very good, with an AUC of 0.906. The figure shows the ROC curve, area under the curve (AUC), sensitivity, and specificity of those who are well adapted to the plateau (HAA), where AUC reflects the screening efficacy. It is generally believed that the larger the AUC of the test, the better its diagnostic value. It fully shows that hsa-miR-4290 in plasma alone as a biomarker for screening those who are well adapted to the plateau (HAA) has certain accuracy and feasibility.
[0099] 3. Figure 5 Comparison of hsa-miR-877-3p expression levels in plasma between the high altitude adaptation (HAA) group and the high altitude adaptation (HAM) group; Figure 5 As shown in the figure, the expression of plasma hsa-miR-877-3p between the high altitude adaptation (HAA) group and the high altitude adaptation (HAM) group was significantly different when P < 0.01. When P < 0.05, there was a significant statistical difference, and when P < 0.01, there was a very significant statistical difference.
[0100] 4. Figure 6 Figure 2 is the operating characteristic curve of hsa-miR-4290 in plasma of people with good altitude adaptation (HAA). Figure 6 As shown in the figure, the screening efficiency of plasma hsa-miR-877-3p for high altitude adaptation (HAA) and high altitude maladaptation (HAM) can be known from the ROC curve. The screening efficiency of plasma hsa-miR-877-3p for high altitude adaptation (HAA) and high altitude maladaptation (HAM) is very good, with an AUC of 0.852. It fully shows that plasma hsa-miR-877-3p alone as a biomarker for screening high altitude adaptation (HAA) has certain accuracy and feasibility.
[0101] 5. Figure 7 is the combined operating characteristic curve of plasma hsa-miR-4290 and hsa-miR-877-3p. Figure 7The ROC curve of the combined screening efficiency of the two microRNAs for people with good plateau adaptation (HAA) and people with poor plateau adaptation (HAM) shows that the combined use of two plasma microRNAs has better screening efficiency for people with good plateau adaptation (HAA) and people with poor plateau adaptation (HAM), with an AUC of 0.955, and has higher accuracy.
[0102] 6. Table 8 shows the receiver operating characteristic curves of each microRNA in the plasma of high altitude well adapted (HAA) and high altitude poor adapted (HAM). Table 9 shows the relative expression of microRNA in high altitude well adapted and poor adapted subjects.
[0103] Table 8 Operating characteristic curve data
[0104]
[0105] Table 9 MicroRNA expression data of people with good and poor plateau adaptation
[0106]
[0107]
[0108] Note: HAA: good plateau adaptation; HAM: poor plateau adaptation; Normal distribution data are expressed as mean ± standard deviation, and non-normal distribution data are expressed as median (interquartile range).
[0109] The present invention screens microRNAs related to plateau adaptability by analyzing and comparing plasma microRNA expression profiles, and then analyzes the expression of each microRNA in a large number of independent plasma samples. Finally, it is verified that hsa-miR-4290 or hsa-miR-877-3p in plasma has a good screening effect between those who are well adapted to the plateau and those who are poorly adapted to the plateau. The combined determination of hsa-miR-4290 and hsa-miR-877-3p two microRNAs can more accurately predict the strength of plateau adaptability and more accurately screen or predict those with good plateau adaptability. These microRNAs have potential clinical value as plasma markers for early screening and early warning evaluation of plateau adaptability.
[0110] The above examples show that hsa-miR-4290 or hsa-miR-877-3p, and the combination of the two have a high predictive value for plateau adaptability, and a screening kit for good plateau adaptation (HAA) or poor plateau adaptation (HAM) can be developed. The kit contains reverse transcription primers for microRNAs, and can also include conventional reverse transcription reagents, such as reverse transcription buffer, reverse transcriptase mixture, RNase-free water, etc. It can also include real-time quantitative qPCR reagents, such as forward primers and reverse primers required for qPCR, and can also include conventional reagents for qPCR amplification detection, such as reverse transcriptase, buffer, dNTPs, MgCl2, ddH2O, fluorescent dyes, Taq enzymes, etc., or commercial conventional supporting reagents.
[0111] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.
Claims
1. Application of hsa-miR-877-3p and hsa-miR-4290 as a biomarker combination in screening individual plateau adaptability after rapid exposure to high altitude.
2. The use according to claim 1, characterized in that The sequence of the hsa-miR-877-3p is shown as SEQ ID No.5, and the sequence of the hsa-miR-4290 is shown as SEQ ID No.
1.
3. Reagents for detecting hsa-miR-877-3p and hsa-miR-4290 are used in the preparation of reagents or kits for screening plateau adaptability.
4. The use according to claim 3, characterized in that: The reagents are primers, probes and / or chips for detecting hsa-miR-877-3p and hsa-miR-4290 respectively.
5. A kit for screening plateau adaptability, characterized in that: The kit comprises reverse transcription primers capable of specifically binding to micronucleic acid molecule biomarkers for reverse transcription, wherein the micronucleic acid molecule biomarkers are hsa-miR-877-3p and hsa-miR-4290.
6. The kit for screening plateau adaptability according to claim 5, characterized in that: The reverse transcription primer sequence is shown as SEQ ID No.2 or SEQ ID No.
6.
7. The kit for screening plateau adaptability according to claim 5, characterized in that: The screening HAA kit comprises primers that can specifically bind to the reverse transcription product of hsa-miR-4290 or hsa-miR-877-3p and perform qPCR amplification.
8. The kit for screening plateau adaptability according to claim 7, characterized in that: The primers include a forward primer and a reverse primer. The forward primer sequence is shown in SEQ ID No.3 or SEQ ID No.7, and the reverse primer sequence is shown in SEQ ID No.4 or SEQ ID No.
8.
9. The kit for screening plateau adaptability according to claim 5, characterized in that: The reverse transcription reaction temperature parameters of the kit are: 42°C for 60 min, 70°C for 10 min.
10. The kit for screening plateau adaptability according to claim 5, characterized in that: The kit also includes 5x reverse transcription Buffer, RTase Mix and RNase-free H2O.
Citation Information
Patent Citations
SNP marker and kit for detecting plateau adaptability
CN113621696A
Navigating a vehicle based on a detected barrier
US10296010B2
